FDA recall record

Stratus Pharmaceuticals Remeven Cream, (50% Urea in a Cream Base), a) 5.0 oz (142 g) and b) recall — FDA D-1464-2016

Crystallization; Complaints that cream appears to have crystallized

Class IIIclassification
D-1464-2016official record ID
Aug 31, 2016report date

Recall record at a glance

Official recordD-1464-2016
CategoryDrug Recalls
ClassificationClass III
FDA record statusCompleted
Recalling firmStratus Pharmaceuticals Inc.
Report dateAug 31, 2016
Recall initiation dateMay 26, 2016
Quantitya) 12,345 tubes; b) 8,578 tubes
LocationMiami, FL, United States

Official product description

Remeven Cream, (50% Urea in a Cream Base), a) 5.0 oz (142 g) and b) 9.0 oz (255 g) tubes, Rx only, Manufactured by Sonar Products Inc, Carlstadt, NJ. Distributed by Stratus Pharmaceuticals Inc., Miami, FL.

Why the product was recalled

Crystallization; Complaints that cream appears to have crystallized

Distribution information

Nationwide and PR

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.